Research programme: viral vaccines - ImmunoBiology
Alternative Names: FluBioVax™; HepBioVax™Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Scancell
- Developer ImmunoBiology
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis C; Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in United Kingdom (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in United Kingdom (Parenteral)
- 17 Oct 2011 ImmunoBiology's viral vaccines are available for licensing as of 17 Oct 2011. http://www.immbio.com